» Articles » PMID: 22629081

Pharmacotherapy for Multidrug Resistant Tuberculosis

Overview
Specialty Pharmacology
Date 2012 May 26
PMID 22629081
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs namely, isoniazid and rifampicin. Emergence of multidrug resistance tuberculosis (MDR-TB) is now a health problem faced by most of the developing countries as well as developed countries across the globe. MDR-TB is a man-made disease that is caused by improper treatment, inadequate drug supplies, and poor patient supervision. HIV infection and AIDS have been implicated as important cause for this. The review of a published literature suggests that the most powerful predictor of treatment of MDR-TB is a history of treatment of TB. Although the treatment is efficacious, there are also a number of adverse effects caused by drugs used in the treatment of MDR-TB.

Citing Articles

Graphene oxide-based electrochemical activation of ethionamide towards enhanced biological activity.

Mulik B, Dhumal S, Sapner V, Rehman N, Dixit P, Sathe B RSC Adv. 2022; 9(61):35463-35472.

PMID: 35528088 PMC: 9074427. DOI: 10.1039/c9ra06681k.


Frequency of Codon 306 Mutations in Gene of Resistant to Ethambutol: A Systematic Review and Meta-Analysis.

Mohammadi B, Ramazanzadeh R, Nouri B, Rouhi S Int J Prev Med. 2020; 11:112.

PMID: 33088440 PMC: 7554598. DOI: 10.4103/ijpvm.IJPVM_114_19.

References
1.
Edwards D, Kirkpatrick C . The immunology of mycobacterial diseases. Am Rev Respir Dis. 1986; 134(5):1062-71. DOI: 10.1164/arrd.1986.134.5.1062. View

2.
Brill K, Li Q, Larkin R, Canaday D, Kaplan D, Boom W . Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via granule-independent mechanisms. Infect Immun. 2001; 69(3):1755-65. PMC: 98082. DOI: 10.1128/IAI.69.3.1755-1765.2001. View

3.
Chelnokova O, Kibrik B . [Use of isofon in combined treatment of patients with acutely progressive forms of tuberculosis]. Probl Tuberk Bolezn Legk. 2003; (9):12-4. View

4.
Koh W, Kwon O, Suh G, Chung M, Kim H, Lee N . Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci. 2004; 19(2):167-71. PMC: 2822294. DOI: 10.3346/jkms.2004.19.2.167. View

5.
Dresser L, Rybak M . The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy. 1998; 18(3):456-62. View